Abstract P4-12-26: A phase II randomized study of lapatinib in combination with capecitabine, vinorelbine or gemcitabine as first or second line-therapy in patients with HER2 positive metastatic breast cancer progressing after taxane (LACOG 0801)

2013 ◽  
Author(s):  
H Gomez ◽  
S Neciosup ◽  
C Tosello ◽  
M Mano ◽  
J Bines ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Metastatic Breast Cancer ◽  
Phase Ii ◽  
Randomized Study ◽  
Metastatic Breast ◽  
Second Line ◽  
Her2 Positive ◽  
Second Line Therapy ◽  
Line Therapy

Trastuzumab and pertuzumab-based versus other therapy as second-line therapy in HER2-positive metastatic breast cancer: A retrospective study from single center.

2015 ◽  
Vol 33 (15_suppl) ◽  
pp. 616-616
Author(s):  
Daniel Fontes Santos De Teive E Argolo ◽  
Lillian Mary Smyth ◽  
Neil M. Iyengar ◽  
Sujata Patil ◽  
Larry Norton ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Metastatic Breast Cancer ◽  
Retrospective Study ◽  
Metastatic Breast ◽  
Second Line ◽  
Single Center ◽  
Her2 Positive ◽  
Second Line Therapy ◽  
Line Therapy

scholarly journals Pertuzumab (P) as ≥ second-line therapy for HER2-positive metastatic breast cancer (mBC): Swiss clinical experience

2019 ◽  
Vol 30 ◽  
pp. iii57
Author(s):  
E.M. Biskup ◽  
C. Montavon Sartorius ◽  
A. Müller ◽  
C. Leo ◽  
C. Uhlmann Nussbaum ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Metastatic Breast Cancer ◽  
Clinical Experience ◽  
Metastatic Breast ◽  
Second Line ◽  
Her2 Positive ◽  
Second Line Therapy ◽  
Line Therapy

N0234: Phase II study of erlotinib (OSI-774) plus gemcitabine as first-or second-line therapy for metastatic breast cancer (MBC)

2005 ◽  
Vol 23 (16_suppl) ◽  
pp. 644-644 ◽  
Author(s):  
D. L. Graham ◽  
D. W. Hillman ◽  
T. J. Hobday ◽  
S. R. Rousey ◽  
S. G. Nair ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Metastatic Breast Cancer ◽  
Phase Ii ◽  
Phase Ii Study ◽  
Metastatic Breast ◽  
Second Line ◽  
Second Line Therapy ◽  
Line Therapy
Sign in / Sign up

Export Citation Format

Share Document